



Elixinol Global to Present at Upcoming U.S. Investor Conferences

SYDNEY, May 9, 2019 – Elixinol Global Limited (EXL or the Company) (ASX:EXL; OTCQX:ELLXF), a global company operating in the industrial hemp, dietary supplements and emerging medicinal cannabis sectors, is attending the following investor conferences in May and June 2019.

3rd Annual Canaccord Genuity Cannabis Conference

When: Tuesday, May 14, 2019

Where: The Grand Hyatt – New York, NY

Presentation: 1:00 p.m. Eastern time

Webcast: Please click [here](#)

Cowen & Co. Toronto Cannabis Summit

When: Wednesday, May 22, 2019

Where: The Westin Harbour Castle – Toronto, ON

Presentation: 1x1 and small group meetings

39th Annual Piper Jaffray Consumer Marketplace Conference

When: Thursday, June 6, 2019

Where: The Pierre Hotel – New York, NY

Presentation: U.S. CBD Players panel at 9:30 a.m. Eastern time

For more information about the conferences or to schedule a one-on-one meeting with EXL's management, please contact your respective conference representative or the Company's U.S. investor relations team at USIR@elixinolglobal.com.

About Elixinol Global

Elixinol Global Limited (ASX:EXL; OTCQX:ELLXF) through its businesses has a global presence in the cannabis industry including hemp-derived CBD dietary supplements, hemp food and wellness products, as well as cultivation and manufacture of medicinal cannabis products. EXL's businesses include:

- Elixinol LLC ("Elixinol"), founded in 2014, is a manufacturer and global distributor of hemp dietary supplement and skincare products, with operations based out of Colorado, USA.
- Hemp Foods Australia Pty Ltd ("Hemp Foods Australia"), founded in 1999, is a leading hemp food wholesaler, retailer, manufacturer and exporter of bulk and branded raw materials, and finished products.
- Nunyara Pharma Pty Ltd ("Nunyara"), formerly known as Elixinol Australia, was founded in 2014 to participate in the emerging Australian medicinal cannabis market and submitted licence applications for cultivation and manufacture to the Office of Drug Control in early 2018. These applications are currently pending approval.



See more at www.elixinolglobal.com

U.S. Investor Relations Contact:

Cody Slach
Managing Director, Gateway IR
USIR@elixinolglobal.com
+1 949 574 3860

Australian Investor Relations Contact:

Glen Zurcher
Account Director, IR Department
IR@elixinolglobal.com
+61 420 249 299

Media Contact:

Chris Husong
Elixinol
chris@elixinol.com
+1 844-804-3504 ext. 420